AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12444940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 9481724 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid daily for 12 weeks
Number of subjects: 35
Study 9481724 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid and 4 g betaine daily for 12 weeks
Number of subjects: 35
Study 9481724 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg folic acid daily for 40 weeks
Number of subjects: 35
Study 9481724 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid daily for 40 weeks
Number of subjects: 35
Study 9481724 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg folic acid daily for four weeks
Number of subjects: 35
Study 8550857 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTS CPC (6.6 mg cetylpyridinium chloride), 2 x daily for 2 hours intra-orally
Number of subjects: 52
Study 8550857 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridex (15 ml, 2 x daily for 30 seconds rinsing)
Number of subjects: 52
Study 8550857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cepacol (1.6 mg cetylpyridinium chloride, 2 x daily lozenges)
Number of subjects: 52
Study 2677961 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based diet containing 6 g/kg of body weight per day of lactose
Number of subjects: 64
Study 2677961 — intervention group
Group type: COMPARATOR
Intervention: Hydrolyzed lactose diet (greater than 95% prehydrolyzed with beta-galactosidase)
Number of subjects: 64
Study 2677961 — intervention group
Group type: COMPARATOR
Intervention: Hydrolyzed lactose diet
Number of subjects: 64
Study 642095 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic aminoglycoside (kanamycin)
Number of subjects: 100
Study 642095 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic antibiotics)
Number of subjects: 100
Study 29757825 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training and education (ET + ED)
Number of subjects: 198
Study 29757825 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone (ET)
Number of subjects: 198
Study 26607102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment (IT) after stepwise drug discontinuation
Number of subjects: 19
Study 26607102 — intervention group
Group type: COMPARATOR
Intervention: Maintenance treatment (MT)
Number of subjects: 19
Study 24823925 — intervention group
Group type: EXPERIMENTAL
Intervention: task‐oriented robot‐supported arm‐hand training
Number of subjects: 16
Study 24823925 — intervention group
Group type: COMPARATOR
Intervention: task‐oriented (unsupported) arm‐hand training
Number of subjects: 16
Study 23601012 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback of personal retinal images
Number of subjects: 25
Study 23601012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 20147417 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious correction group
Number of subjects: 3
Study 20147417 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction group
Number of subjects: 3
Study 20147417 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 18155963 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 microg rdESAT-6
Number of subjects: 15
Study 18155963 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 microg rdESAT-6
Number of subjects: 15
Study 18155963 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg rdESAT-6
Number of subjects: 15
Study 18155963 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin (2 TU)
Number of subjects: 15
Study 18155963 — intervention group
Group type: EXPERIMENTAL
Intervention: rdESAT-6 (10 microg)
Number of subjects: 15
Study 18155963 — intervention group
Group type: EXPERIMENTAL
Intervention: rdESAT-6 (all doses)
Number of subjects: 15
Study 18155963 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin
Number of subjects: 15
Study 18155963 — intervention group
Group type: EXPERIMENTAL
Intervention: rdESAT-6
Number of subjects: 15
Study 15665706 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 1009
Study 15665706 — intervention group
Group type: COMPARATOR
Intervention: Cefprozil
Number of subjects: 1009
Study 15665706 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 1009
Study 15665706 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 1009
Study 12499323 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal-iron peanut butter-based diet
Number of subjects: 77
Study 12499323 — intervention group
Group type: COMPARATOR
Intervention: Olive oil diet
Number of subjects: 77
Study 12499323 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron status measures (ferritin, iron, TIBC, NTBI)
Number of subjects: 77
Study 10817444 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 1058
Study 10817444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 1058
Study 10817444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058
Study 9102031 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial pure titanium implants
Number of subjects: 281
Study 9102031 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel implants
Number of subjects: 281
Study 2050913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7040157 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (1 mg/kg)
Number of subjects: 410
Study 7040157 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (hydration and tetracycline)
Number of subjects: 410
Study 30354530 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% DSP-Visulex
Number of subjects: 44
Study 30354530 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% DSP-Visulex
Number of subjects: 44
Study 30354530 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate (PA)
Number of subjects: 44
Study 30058437 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/remifentanil anesthesia
Number of subjects: 67
Study 30058437 — intervention group
Group type: COMPARATOR
Intervention: TIVA (propofol/remifentanil) anesthesia
Number of subjects: 67
Study 26254238 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aids (PtDA)
Number of subjects: 343
Study 26254238 — intervention group
Group type: COMPARATOR
Intervention: Control (usual education)
Number of subjects: 343
Study 24679880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolution therapy with potassium sodium hydrogen citrate at a dose of 1 mEq/kg per day for 1 to 3 months
Number of subjects: 87
Study 24679880 — intervention group
Group type: COMPARATOR
Intervention: Shock wave lithotripsy using a Lithotripter S under general anesthesia
Number of subjects: 87
Study 23059918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone ointment (5 g tube containing 5 mg dexamethasone)
Number of subjects: 240
Study 23059918 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 240
Study 20491229 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (GaAIAs ‐ 780 nm) applied on the temporalis and masseter muscles, energetic doses of 25 J/cm2 and 60 J/cm2, applied twice a week for four weeks
Number of subjects: 48
Study 20491229 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 48
Study 18976996 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel training
Number of subjects: 24
Study 18976996 — intervention group
Group type: COMPARATOR
Intervention: Weight-lifting training
Number of subjects: 24
Study 16093742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sexual abuse
Number of subjects: 649
Study 16093742 — intervention group
Group type: EXPERIMENTAL
Intervention: Documented maltreatment
Number of subjects: 649
Study 16093742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical abuse
Number of subjects: 649
Study 11978902 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate treatment for 3 years
Number of subjects: 1000
Study 11955465 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 125 microg/kg
Number of subjects: 36
Study 11955465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9592638 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient management (group A)
Number of subjects: 114
Study 9592638 — intervention group
Group type: COMPARATOR
Intervention: Outpatient management (group B)
Number of subjects: 114
Study 7642415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemo-radiotherapy (Cisplatin 20 mg/mq and 5-Fluorouracil 200 mg/mq daily for 5 days) with two cycles of 20 Gy/10 fractions/12 days each.
Number of subjects: 76
Study 7642415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemo-radiotherapy (Cisplatin 20 mg/mq and Methotrexate 40 mg/mq instead of 5-Fluorouracil) with two cycles of 25 Gy/10 fractions/12 days each.
Number of subjects: 76
Study 7642415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemo-radiotherapy (Cisplatin and 5-Fluorouracil) with varying radiotherapy schedules.
Number of subjects: 76
Study 2787514 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Group (n = 17)
Number of subjects: 67
Study 2787514 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic Group (n = 17)
Number of subjects: 67
Study 2787514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Group (n = 17)
Number of subjects: 67
Study 2787514 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n = 16)
Number of subjects: 67
Study 582983 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 16
Study 582983 — intervention group
Group type: EXPERIMENTAL
Intervention: tolbutamide
Number of subjects: 16
Study 582983 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen + tolbutamide
Number of subjects: 16
Study 30908611 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 125
Study 30908611 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 125
Study 30908611 — intervention group
Group type: COMPARATOR
Intervention: Mechanochemical ablation (MOCA)
Number of subjects: 125
Study 28874146 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-biofeedback
Number of subjects: 27
Study 28874146 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitative treatment alone (control)
Number of subjects: 27
Study 26124031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive force of 125 g (light)
Number of subjects: 20
Study 26124031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusive force of 250 g (heavy)
Number of subjects: 20
Study 26124031 — intervention group
Group type: COMPARATOR
Intervention: No force applied (control group)
Number of subjects: 20
Study 24080858 — intervention group
Group type: EXPERIMENTAL
Intervention: Red laser treatment
Number of subjects: 30
Study 24080858 — intervention group
Group type: COMPARATOR
Intervention: Green laser treatment
Number of subjects: 30
Study 21192139 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (up to 200 mg daily)
Number of subjects: 134
Study 21192139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 19581310 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent three-dimensional conformal radiotherapy (3D‐CRT) and androgen deprivation (AD)
Number of subjects: 52
Study 19581310 — intervention group
Group type: EXPERIMENTAL
Intervention: Short neoadjuvant androgen deprivation (SNAD) (<=3 months)
Number of subjects: 52
Study 19581310 — intervention group
Group type: COMPARATOR
Intervention: Long neoadjuvant androgen deprivation (LNAD) (>3 months)
Number of subjects: 52
Study 17180695 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic remedy
Number of subjects: 144
Study 17180695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 15541220 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatographically purified rabies vaccine (CPRV)
Number of subjects: 135
Study 15541220 — intervention group
Group type: COMPARATOR
Intervention: Human diploid cell vaccine (HDCV)
Number of subjects: 135
Study 11975819 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 minutes of bilateral intraoral chilling
Number of subjects: 35
Study 11975819 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral sumatriptan
Number of subjects: 35
Study 11975819 — intervention group
Group type: COMPARATOR
Intervention: Sham (tongue) chilling
Number of subjects: 35
Study 9402268 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hFSH
Number of subjects: 235
Study 9402268 — intervention group
Group type: COMPARATOR
Intervention: u-hFSH HP
Number of subjects: 235
Study 7963911 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Mycobacterium leprae, BCG, or a combination of the two (vaccination)
Number of subjects: 893
Study 7963911 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated (control group)
Number of subjects: 893
Study 7963911 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated, lepromin-negative contacts (control subgroup)
Number of subjects: 893
Study 7963911 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination (overall effect)
Number of subjects: 893
Study 7963911 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination (specific effect on lepromatous leprosy)
Number of subjects: 893
Study 2441535 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol (160‐320 mg p.o.) + mexiletine (600‐800 mg p.o.)
Number of subjects: 34
Study 2441535 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol (160‐320 mg p.o.) + tocainide (800‐1200 mg p.o.)
Number of subjects: 34
Study 2441535 — intervention group
Group type: COMPARATOR
Intervention: sotalol/mexiletine
Number of subjects: 34
Study 2441535 — intervention group
Group type: COMPARATOR
Intervention: sotalol/tocainide
Number of subjects: 34
Study 2441535 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol/mexiletine and sotalol/tocainide
Number of subjects: 34
Study 30928284 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous RRT
Number of subjects: 41
Study 30928284 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 41
Study 29992272 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1000 mg twice daily for 12 weeks
Number of subjects: 40
Study 29992272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27822169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (8 mmol·potassium nitrate·d‐1)
Number of subjects: 0
Study 27822169 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric placebo
Number of subjects: 0
Study 24796849 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect at time j
Number of subjects: 302
Study 24796849 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking urge at time j
Number of subjects: 302
Study 22206748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile infusion of oxytocin
Number of subjects: 520
Study 22206748 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of oxytocin
Number of subjects: 520
Study 20184764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascading of a multi‐professional training package to enhance midwifery and obstetric skills in the assessment, repair and postnatal management of perineal trauma.
Number of subjects: 0
Study 18602511 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 cc of gin (18.5 g of ethanol)
Number of subjects: 45
Study 18602511 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 cc of red wine (18.9 g of ethanol)
Number of subjects: 45
Study 18602511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (120 cc of water)
Number of subjects: 45
Study 15857851 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eptifibatide given in the emergency room
Number of subjects: 102
Study 15857851 — intervention group
Group type: COMPARATOR
Intervention: Late or no eptifibatide
Number of subjects: 102
Study 15857851 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eptifibatide
Number of subjects: 102
Study 12637206 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching an 83‐minute horror film (The Texas Chainsaw Massacre, 1974)
Number of subjects: 32
Study 12637206 — intervention group
Group type: COMPARATOR
Intervention: Sitting quietly in a room (control group)
Number of subjects: 32
Study 10709856 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g/day of elemental calcium)
Number of subjects: 0
Study 10709856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8775164 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A: Cycling at 75% Wmax until exhaustion
Number of subjects: 30
Study 8775164 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B: Preload of 45 min at 70% Wmax followed by 15 min of maximal work
Number of subjects: 30
Study 8775164 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C: Time trial to complete a preset amount of work as fast as possible
Number of subjects: 30
Study 1477851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60 or 90 mg p.o. q.i.d.)
Number of subjects: 12
Study 1477851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6716067 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum exercise stress test (MEST)
Number of subjects: 0
Study 6716067 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 3537442 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (30 sessions over 10 weeks)
Number of subjects: 41
Study 3537442 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 41
Study 3537442 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained patients (exercise group)
Number of subjects: 41
Study 31785116 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cefuroxime
Number of subjects: 11
Study 31785116 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbound cefuroxime
Number of subjects: 11
Study 30193176 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying a load with 10% body mass
Number of subjects: 29
Study 30193176 — intervention group
Group type: COMPARATOR
Intervention: Carrying no load (CON)
Number of subjects: 29
Study 30193176 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying a load with no added weight (empty box)
Number of subjects: 29
Study 30193176 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying a load with 5% body mass
Number of subjects: 29
Study 28631453 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-dexmedetomidine (PD group)
Number of subjects: 60
Study 28631453 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil (PR group)
Number of subjects: 60
Study 26041041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent genogroup 1 genotype 1 (GI.1)/GII.4 norovirus vaccine (50 μg of VLPs of each strain)
Number of subjects: 100
Study 26041041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26041041 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent genogroup 1 genotype 1 (GI.1)/GII.4 norovirus vaccine
Number of subjects: 100
Study 23942074 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin±bevacizumab
Number of subjects: 759
Study 21388734 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited English proficient callers
Number of subjects: 971
Study 21388734 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited English proficient callers attempting bystander CPR
Number of subjects: 971
Study 21388734 — intervention group
Group type: COMPARATOR
Intervention: English-fluent callers
Number of subjects: 971
Study 21388734 — intervention group
Group type: COMPARATOR
Intervention: English-fluent callers attempting bystander CPR
Number of subjects: 971
Study 18633677 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased monocyte chemoattractant protein-1 ratio
Number of subjects: 101
Study 18633677 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant protein-1 ratio
Number of subjects: 101
Study 18633677 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen levels
Number of subjects: 101
Study 18633677 — intervention group
Group type: EXPERIMENTAL
Intervention: Serosal invasion
Number of subjects: 101
Study 18633677 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant protein-1 expression
Number of subjects: 101
Study 16933188 — intervention group
Group type: EXPERIMENTAL
Intervention: Viasys‐Jäger‐APS system
Number of subjects: 30
Study 16933188 — intervention group
Group type: EXPERIMENTAL
Intervention: AKITA‐System (controlled inhalations)
Number of subjects: 30
Study 11911356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric infusion of Lipofundin S 20% (306 kcal)
Number of subjects: 19
Study 11911356 — intervention group
Group type: COMPARATOR
Intervention: Intragastric infusion of saline
Number of subjects: 19
Study 11911356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraesophageal infusion of 0.2 N HCl with Lipofundin S 20%
Number of subjects: 19
Study 11911356 — intervention group
Group type: COMPARATOR
Intervention: Intraesophageal infusion of 0.2 N HCl diluted in saline
Number of subjects: 19
Study 10374374 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (n = 52)
Number of subjects: 101
Study 10374374 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n = 49)
Number of subjects: 101
Study 7714309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT); Components: cognitive restructuring and assertion training; Population size: 24
Number of subjects: 33
Study 7714309 — intervention group
Group type: COMPARATOR
Intervention: Information‐Focused Therapy (IFT); Components: relaxation training, nutritional and vitamin guidelines, dietary and lifestyle recommendations, aspects of child management training and assertion training; Population size: 9
Number of subjects: 33
Study 2623126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-paced music
Number of subjects: 114
Study 2623126 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-paced music
Number of subjects: 114
Study 2623126 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 114
Study 2623126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock condition
Number of subjects: 114